THE WOODLANDS, Texas, Feb. 24, 2011 /PRNewswire/ — Lexicon Pharmaceuticals, Inc.
(Nasdaq:
LXRX), a biopharmaceutical company focused on discovering and
developing breakthrough treatments for human disease, today updated
its drug development progress and reported financial results for
the three months and year ended December 31, 2010.
“We achieved significant progress in the advancement of our drug
pipeline in 2010, led by positive results in clinical trials of
LX4211 for type 2 diabetes,” said Dr. Arthur T.
Sands, president and chief executive officer of Lexicon. “We
also reported the results of a Phase 2a trial of LX2931 in
rheumatoid arthritis, demonstrating a preliminary signal of
efficacy and favorable safety profile that we believe supports
exploration of higher doses in future studies.”
Key Developments of 2010
Lexicon reported positive results from a Phase 2a clinical trial of
LX4211,
a dual inhibitor of sodium-glucose cotransporters 1 and 2, showing
statistically significant and rapid improvements in multiple
parameters in patients with
type 2 diabetes, including significant reductions of HbA1c
within four weeks. Lexicon also reported positive results
from a mechanistic study of a tablet formulation of LX4211, showing
significantly increased levels of GLP-1 and PYY, important
mediators of glycemic and appetite control. Lexicon plans to
initiate a Phase 2b study of LX4211 around mid-year 2011. Lexicon
continued its efforts to develop an improved formulation of LX1031,
an inhibitor of tryptophan hydro
‘/>”/>
SOURCE